



Europäisches Patentamt
European Patent Office
Office européen des brevets

2

(11) Publication number:

0 073 169

A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 82401547.3

(51) Int. Cl.³: A 61 K 39/095

(22) Date of filing: 18.08.82

(30) Priority: 20.08.81 US 294855

(43) Date of publication of application:
02.03.83 Bulletin 83/9

(68) Date of deferred publication of search report: 20.06.84

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: MERCK & CO. INC.
126, East Lincoln Avenue P.O. Box 2000
Rahway New Jersey 07065(US)

(72) Inventor: O'Rourke, Edwards C.
664 Jones Avenue
West Point Pennsylvania 19486(US)

(72) Inventor: Fullerton, Wardle W.
5851D Christa Court
La Mesa California 92041(US)

(74) Representative: Martin, Jean-Jacques et al,
Cabinet REGIMBEAU 26, Avenue Kléber
F-75116 Paris(FR)

(54) Immunogenic complex from *N. gonorrhoeae*.

(57) A vesicular, immunogenic, non-pyrogenic complex is obtained from isolates of *N. gonorrhoeae* by cultivating *N. gonorrhoeae* on a suitable nutrient medium; harvesting and centrifuging the cells; extracting the cell pellet with TRITON X-100 at alkaline pH; suspending the solids remaining after extraction in aqueous medium and precipitating in the cold with ethanol.

EP 0 073 169 A3

A10

THE UNIVERSITY OF CHICAGO
LIBRARY
540 EAST 57TH STREET
CHICAGO, ILL. 60637
TEL. 773-936-5000
FAX 773-936-5001
WWW.CHICAGO.EDU

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11) Publication number:

0 073 169**A2**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 82401547.3

(51) Int. Cl.³: A 61 K 39/095

(22) Date of filing: 18.08.82

(30) Priority: 20.08.81 US 294855

(43) Date of publication of application:
02.03.83 Bulletin 83/9(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE(71) Applicant: MERCK & CO. INC.
126, East Lincoln Avenue P.O. Box 2000
Rahway New Jersey 07065(US)(72) Inventor: O'Rourke, Edwards C.
664 Jones Avenue
West Point Pennsylvania 19486(US)(72) Inventor: Fullerton, Wardle W.
5851D Christa Court
La Mesa California 92041(US)(74) Representative: Martin, Jean-Jacques et al,
Cabinet REGIMBEAU 26, Avenue Kléber
F-75116 Paris(FR)(54) Immunogenic complex from *N. gonorrhoeae*.

(57) A vesicular, immunogenic, non-pyrogenic complex is obtained from isolates of *N. gonorrhoeae* by cultivating *N. gonorrhoeae* on a suitable nutrient medium; harvesting and centrifuging the cells; extracting the cell pellet with TRITON X-100 at alkaline pH; suspending the solids remaining after extraction in aqueous medium and precipitating in the cold with ethanol.

TITLE OF THE INVENTIONIMMUNOGENIC COMPLEX FROM N. GONORRHOEAE5 BACKGROUND OF THE INVENTION

10 A vesicular, immunogenic, non-pyrogenic complex is obtained from isolates of N. gonorrhoeae by cultivating N. gonorrhoeae on a suitable nutrient medium; harvesting and centrifuging the cells; extracting the cell pellet with TRITON X-100 at alkaline pH; suspending the solids remaining after extraction in an aqueous medium and precipitating in the cold with ethanol.

15 The instant invention relates to a novel vesicular, immunogenic, non-pyrogenic complex obtained from isolates of N. gonorrhoeae. More particularly, the instant invention relates to said immunogenic complex; to the process for obtaining said immunogenic complex from isolates of N. gonorrhoeae; and to compositions for the safe and effective

20

administration of said immunogenic complex to mammalian species in order to provide protection against N. gonorrhoeae.

5 The instant invention is based upon applicant's discovery that a vesicular, immunogenic, non-pyrogenic complex may be obtained from isolates of N. gonorrhoeae by cultivating an isolate of N. gonorrhoeae on a suitable nutrient medium; harvesting and centrifuging the cells; extracting the cells with
10 TRITON X-100 (polyoxyethylene octyl phenol, a non-ionic detergent) at alkaline pH; suspending the solids remaining after extraction in an aqueous medium and precipitating in the cold with ethanol; and releasing and removing RNA and DNA by nuclease
15 digestion followed by diafiltration to remove the enzymes and degradation products. The material is then dispersed and solubilized by sonication and filtered through a 0.45 μ m polysulphone membrane. It is contemplated that immunogenically effective
20 amounts of the complex of this invention in suitable formulations will be administered as a vaccine against N. gonorrhoeae infection.

Procedures for cultivating isolates of N. gonorrhoeae and for producing the immunogenic complex
25 of this invention therefrom are described in detail below.

FERMENTATION OF N. GONORRHOEAEA. Preparation of Inoculum For Fermentation

- 5 1. Swab GCIV agar plates (23) with N.
gonorrhoeae stock culture.
2. Incubate plates for about 17 hours in an 8%
CO₂ water saturated CO₂ incubator.
3. Harvest the cells from the surface of the
10 plates; pool the collected cells and transfer to 700
ml of fermentation broth in a 1000 ml nephelometer
flask. The fermentation broth consists of
Mueller-Hinton broth (DIFCO) containing, per 1000 ml
final volume, 30 ml of 7.5% aqueous NaHCO₃ and 11
15 ml of IsoVitalex (Baltimore Biological Laboratories,
Baltimore, Maryland).
4. Remove 350 ml from the flask and transfer to
a second 1000 ml nephelometer flask.
5. Place both flasks in a shaker water bath at
20 37°C. with 160-200 oscillations per minute (1/2 inch
stroke).
6. Monitor growth by measuring optical density
at 15 minute intervals. Stop the incubation when the
optical density is 0.2 to 0.4.

25

B. 7-Liter Fermentation

- Add the pooled contents from the shake
flasks obtained above to 7 liters of fermentation
30 broth (the broth is the same as that used in pre-
paring the inoculum). Ferment at 37°C. with stirring

at 450 rpm while passing air (2.9 liter/min.) and CO₂ (0.6 liters/min.) through the medium. Continue fermentation for about 5 hours or until the bacteria reach their stationary phase of growth. Inactivate
5 the bacteria by adding thimerosal (final concentration 1/5000) and store overnight at 5°C with gentle mixing. Transfer the broth immediately into 500 ml centrifuge tubes. Centrifuge at 5000xg for 20 minutes at 2°C.

10 Although the fermentation technique described above is the preferred means for cultivating the N. gonorrhoeae used in preparing the immunogenic complex of this invention, it will be obvious that the N. gonorrhoeae also can be obtained by agar
15 growth. Thus, for example, uncontaminated GCIV agar plates may be streaked with N. gonorrhoeae seed culture and incubated at 37°C. for 16-18 hours. The harvested cells from such plates then may be used in the preparation of the immunogenic complex of this
20 invention.

The immunogenic complex of this invention is prepared by the techniques described below. All procedures are conducted with aseptic techniques.

25 PREPARATION OF IMMUNOGENIC COMPLEX

A. Preparation of 5000xg Pellet (Done At 2-8°C)

At the end of the fermentation described above, fill 12 gas sterilized 500 ml centrifuge bottles
30 having sealing caps with fermentation broth and centrifuge at 5000xg at 2°C. for 20 minutes. Decant

the supernatants. Pool the pellets by scraping into two 500 ml centrifuge bottles having sealing caps. Resuspend the pellets by mixing while gradually adding 400 ml of physiological saline to each centrifuge bottle. Store the GC material at -70°C . until needed. Thaw and centrifuge at 5000xg for 20 minutes. Decant the supernatant to obtain saline washed 5000xg pellets.

10 B. Treatment With Triton X-100 (Done At Room Temperature Except Where Noted)

Prepare on the same day the following solution. Add 17.5 ml of TRITON X-100 (non-ionic detergent, polyoxyethylene octyl phenol, Rohm & Haas Co., Philadelphia, Penna.) to about 320 ml of sterile pyrogen-free deionized water with stirring. Add 1.75 ml 2 molar tris(hydroxymethyl)-aminomethane and 3.5 ml 1 molar MgCl_2 . When the TRITON X-100 is completely dissolved, adjust the pH to 8.5 with 1 normal HCl. Adjust the final volume to 350 ml with additional deionized water and filter through a $0.2\ \mu\text{m}$ membrane filter to sterilize.

25 Transfer the 5000xg pellets obtained above to a beaker. Rinse the centrifuge bottles with small volumes of TRITON X-100 solution and transfer to the beaker. Mix the 5000xg pellets with the solution to form a thick paste, then gradually add a total of 300 ml of TRITON X-100 solution. Stir rapidly for 30 minutes. Avoid foaming. Transfer about 40 ml of the

resulting mixture to each of 8 screw-cap polycarbonate centrifuge tubes and centrifuge at 48,000xg for 20 minutes at 2-8°C. Decant the supernatant.

5 C. Treatment with Ethanol (Done At Room Temperature Except Where Noted)

10 Add 2 ml of physiological saline to each tube and dislodge the pellets. Pour the pellets into a 15 ml dounce-type tissue grinder and homogenize briefly to resuspend. Transfer the homogenate to a 1000 ml flask. Rinse the tissue grinder with physiological saline and add the rinses to the flask. Adjust final
15 volume to 100 ml with physiological saline and add 400 ml of absolute ethanol at -20°C. mixing well. Place flask at -20°C. overnight.

20 Shake the flask well to suspend evenly the precipitate. Collect the ethanol precipitate by centrifugation in 150 ml bottles at 2500xg for 20 minutes at 2-8°C. Decant the supernatant. Break up the pellets while adding cold 80% ethanol (at least 100 ml per bottle. When a fine, homogenous suspension is obtained, centrifuge at 2500xg for 20 minutes
25 at 2-8°C. Decant the supernatant.

D. Nuclease Treatment and XM-300 Diafiltration (Done At Room Temperature)

30 Suspend the washed ethanol precipitate pellets obtained above in 20 ml phosphate buffer (0.062 molar sodium phosphate, pH 7.0) containing 0.02 mole of

MgCl₂ using a dounce-type tissue grinder or a glass stirring rod. Prepare the nuclease treatment reaction mixture so as to contain about 3.5 mg/ml protein (Lowry) as follows.

5

16.6 ml Suspended Ethanol (8.73 mg/ml)
 Precipitate Pellet

10

22.0 ml Phosphate Buffer
 with MgCl₂

1.7 ml DNase (1 mg/ml) (Sterile)

1.7 ml RNase (1 mg/ml) (Sterile)

15

Incubate at room temperature for 1 hour with frequent gentle stirring in a 100 ml beaker.

20

After incubation, load the reaction mixture directly into a sterile thin channel ultrafiltration cell fitted with an AMICON XM-300 membrane (Amicon Corporation, Lexington, Massachusetts). Dilute the reaction mixture to 400 ml with phosphate buffer. Begin running the unit in the diafiltration mode using phosphate buffer at 10 psi (pounds per in²)

25

and the highest pump speed compatible with this pressure. Run, collecting at least 7 diavolumes of ultrafiltrate. Change to sterile pyrogen-free deionized water. Increase the pressure to 20 psi with increased pump speed. Run, collecting at least 7 diavolumes of ultrafiltrate. Stop diafiltration

30

and change to concentration mode. Concentrate at 20 psi to 50 ml. Remove the sample and rinse the cell with 25 ml of the deionized water. Pool the sample and rinses to obtain 107 ml of XM-300 retentate (1.18 mg/ml LOWRY protein). Store the retentate at 2-8°C.

E. Probe Sonication And Filtration

(Done At Room Temperature Except Where Noted)


5 Add 2 ml of the retentate obtained above to
2 gm of acid washed glass beads (0.1 to 0.11 mm
diameter) in a 16x125 mm tube. Sonicate using a
standard microtip at an output setting of 7 (about 32
watts) for 15 minutes with the tube immersed in an
ice-water bath. Add 2 ml of cold deionized water to
10 the sample and mix well. Pipet off the supernatant
and filter through Nalgene 115 ml filter units fitted
with a 0.45 polysulphone μ m membrane. Rinse the
beads twice with 2 ml of the deionized water and
filter the supernatants through the same filter
15 unit. Repeat the process until all of the XM-300
retentate is processed to obtain the final product
(159 ml, 0.24 mg/ml LOWRY protein).

 Alternatively, the XM-300 retentate from
Step D may be treated by conventional flow sonication
20 techniques or in an ultrasonic cleaner bath at 50-55
KHZ.

25

30

The process described above may be summarized as follows:



Nuclease Treated Product



Retentate

5

Diafiltration on XM-300
(a) physiological saline
(b) H₂O

25%



10

Sonication Product



15

Final Product in Water
0.45μ filtered

15%

20

25

30

CHEMICAL-PHYSICAL ANALYSIS OF ISOLATED COMPLEXA. Composition As % of Dry Weight (XM-300 Retentate-Fermentor Grown)

5

Protein (Lowry) 70-90

Total Carbohydrate (Phenol-H₂SO₄) 1.5-5.5

10

Ketodeoxyoctanoate
(Thiobarbituric Acid Method) 0.45-0.55

RNA (Orcinol) 1.1-1.6

15

DNA (DIPHENYLAMINE) 0-1.5

Total Lipid
(Sulpho-Phospho-Vanillin) 0.4-3.5

20

Total Phosphate 0.4-0.65

Hexosamines 1.0-3.5

25

Metals (X-Ray Fluorescence P, S, Si
Al and Fe variable

TRITON X-100 < 0.04

30

B. SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS
OF ISOLATED COMPLEX

5 Vaccine preparations can be characterized and
analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis according to the method of Weber and
Osborn [J. Biol. Chem. 244:4406(1969)]. With this
method at least 27 bands can be readily observed in
10 the isolated complex of this invention. The bands
are distributed throughout the length of the gel and
their calculated sub-unit molecular weights range
from over 150,000 to less than 14,000. In general,
the patterns of the bands are similar for material
isolated from different strains whether grown on agar
15 or in liquid media. However, variations may be
observed: there may be differences in the amount of
a particular band present in different preparations;
one or two bands may be present in some preparations
and not in others; and, a band may show slight differ-
20 ences in molecular weight in different preparations.
In all cases, the pattern is dominated by a strongly
staining band with a molecular weight in the range
35,000 to 39,000. This band is the subunit poly-
peptide of the major protein of the outer membrane.
25 Other prominent bands occur with the following
approximate weights: 150,000; 115,000; 90,000;
70,000; 45,000; 32,000-22,000, a group of four
bands; and 20,000-15,000, a group of 2 to 3 diffuse
bands.

ANTIGENICITY OF ISOLATED COMPLEX

The antigenicity of the isolated complex of this invention conveniently may be measured by standard serum bactericidal antibody (SBA) assay employing conventional techniques:

Typical results of such assay are shown in the following table:

SERUM BACTERICIDAL ANTIBODY (SBA)RESPONSES OF GUINEA PIGS

To N. gonorrhoeae (Strain 340) - Three Doses

15	<u>Sample</u>	<u>Dose</u>	<u>SBA</u>
		<u>mcg Protein</u>	
	Starting Material	100	$\geq 1:640$
	(5000xg pellet)	20	1:160
20	Probe Sonicated	100	$\geq 1:640$
	and filtered	20	1:160
	Saline Placebo	---	$< 1:5$

OPSONIC ACTIVITY OF ISOLATED COMPLEX

A standardized gonococcal strain is incubated with various heat-inactivated test serum samples. The serum-treated gonococci are injected intravenously into 11-day old chick embryos. The eggs are incubated and subsequently observed for viability. Where specific opsonic antibody activity exists in adequate amounts, the chick embryos are protected from an otherwise lethal challenge of gonococci. Results of a typical assay as shown in the following table.

- 14 -

16180

OPSONIC ACTIVITY OF GC (strain 340)
 FERMENTER GROWN FRACTIONS IN
 GUINEA PIGS ADMINISTERED
INTRAPERITONEALLY THREE TIMES

5

	SAMPLE	FRACTION	PROTEIN	BLEEDING	OPSONIN TITER
			(mcg/ml)		(Chick embryo)
10	168-2	Starting Material (5000xg Pellet)	100	Pre	1:127
				Post	1:2560
15	168-10	Sonicated-Filtered XM-300 RTT(ETOH)	100	Pre	1:180
				Post	1:2032
20	CM-258	Placebo	-	Pre	1:143
				Post	1:90

5

10

15

2

PYROGENICITY OF ISOLATED COMPLEX

The pyrogenicity of the immunogenic complex of
 this invention conveniently may be measured by the
 standard rabbit pyrogen test employing conventional
 techniques. Typical results of the rabbit pyrogen test
 are shown in the following table.

30

RABBIT PYROGEN ASSAY
NEISSERIA GONORRHOEAE VACCINE
(strain Melvin)²

5	SAMPLE	*MPD	Maximum Temp. Rise (°C)
	Vaccine		
	Lot 781	0.05	0.1°, 0.2°, 0.3°
10		0.025	0.0°, 0.0°, 0.2°
	Placebo	-	0.1°, 0.6°, 0.1°
	(M-258)		
	(10 ml-1 Kg Body Wt.)		
15			

* MPD-Minimum pyrogenic dose-mcg protein/ml/kg rabbit

IMMUNOGENIC ACTIVITY OF ISOLATED COMPLEX

20 Chimpanzees received five injections (lot 781, strain Melvin, 148 mcg gonococcal protein per injection) on a weekly basis. Nineteen days after the last injection all chimpanzees (including placebo controls)

25 received a live challenge of virulent gonococci intraurethrally. All chimpanzees were bacteriologically cultured. All six vaccinees were free of gonococcal infection while five of six placebo injected chimpanzees were positive for gonococcal infection.

30 Statistically significant immunogenic response was achieved in the vaccinees. These results are summarized in the following table.

ANTIBODY RESPONSES AND INFECTION
 PATTERNS OF CHIMPANZEES THAT
 WERE IMMUNIZED (NEISSERIA
 GONORRHOEAE VACCINE-LOT 781)
 AND CHALLENGED

5

	Chimp No.	Immunization Status	Serology & Infection Status	Challenge Period-Day	
				47	53
10	010	Vaccinee	*Bactericidal	1:40	-
			**Opsonin	1:1525	-
			Infection	0	0
15	029	Vaccinee	Bactericidal	1:40	-
			Opsonin	1:904	-
			Infection	0	0
20	055	Vaccinee	Bactericidal	1:80	-
			Opsonin	1:2560	-
			Infection	0	0
25	056	Vaccinee	Bactericidal	1:40	-
			Opsonin	1:452/1:1662	-
			Infection	0	0
30	062	Vaccinee	Bactericidal	1:40	-
			Opsonin	1:411/1:1072	-
			Infection	0	0
	072	Vaccinee	Bactericidal	1:40	-
			Opsonin	1:1436	-
			Infection	0	0

Chimp No.	Immunization Status	Serology & Infection Status	Challenge Period-Day	
			47	53
5				
10	030	Placebo Bactericidal Opsonin Infection	< 1:5	0
			< 1:320	-
			0	3+
15	034	Placebo Bactericidal Opsonin Infection	< 1:5	-
			1:398	-
			0	+
20	035	Placebo Bactericidal Opsonin Infection	< 1:5	-
			< 1:320	-
			0	3+
25	066	Placebo Bactericidal Opsonin Infection	1:5	-
			1:398/1:320	-
			0	0
30	073	Placebo Bactericidal Opsonin Infection	< 1:5	-
			1:356/1:320	-
			0	4+
30	074	Placebo Bactericidal Opsonin Infection	< 1:5	-
			1:356	-
			0	4+

*Bactericidal - a dash indicates no bleeding for that date; all pre-titers (day 0) < 1:2.5.

**Opsonin - when the pre-immunization titer was other than 1:320 varied it is presented above the post-immunization value for that day. A dash indicates no bleeding for that date.

5

Infection key:

	<u>±</u>	50 gonococcal colonies (two urethral cultures)				
	1+	51-200	"	"	"	"
	2+	201-500	"	"	"	"
10	3+	501-750	"	"	"	"
	4+	750	"	"	"	"

5

1

15

20

25

30

162
The immunogenic complex of this invention may be sterilized by filtration and preserved with, for example, thimerosal (0.005%), phenol (0.25%), methyl parabens (0.1%) propyl parabens (0.02%), thiocid (0.01%), phenoxyethanol (0.375%), benzyl alcohol (0.9%), benzanthonium chloride (0.025%), formaldehyde (0.005%) and the like; thimerosal, thiocid, phenoxyethanol and the methyl and propyl parabens being preferred, and may be subdivided into suitable containers for distribution as a vaccine. As a vaccine, it may be administered as an injectable in a suitable physiologically acceptable medium such as, for example, phosphate buffered saline and the like, either alone or in combination with adjuvants well-known in the art such as, for example, alum which may be employed in an amount sufficient to afford up to 1.25 mg of aluminum by assay per dose.

Typically, in the preparation of vaccines, the immunogenic complex of this invention is moved from the filtration step described above to alum adsorption by adjusting the pH of the suspension (Step E, above) to about pH 7.0 by slowly adding 0.01N hydrochloric acid. The volume of pre-formed alum required for adsorption may be calculated using the formula:

$$Z = \frac{Y \cdot X}{1500}$$

wherein Y = volume of immunogenic complex (ml)
X = Lowry protein (mcg/ml)
Z = volume of preformed alum (ml)

5 Slowly add the pre-formed alum (4.55 mg Al^{+++} /ml) and titrate with 0.1N sodium hydroxide in order to maintain the pH in the 6.2-6.8 range. When all the alum has been added, adjust to a final pH of 6.2. Mix the suspension for three hours at room temperature. Centrifuge at 1500xg for 20 minutes. Resuspend the pellet in sterile, isotonic saline to a final volume of 10 x z. Add thimerosal to a final concentration of 1:20,000.

10 Immunogenic response is achieved in adult humans by injection of 0.25 to 3.0 ml unit doses proportioned so as to deliver from 5 to 500 mcg protein per dose. Typically, 0.5 ml doses containing 50 mcg protein are employed. Two to three unit dose
15 injections over a 1 to 3 month period are employed in order to impart a primary immunogenic response and, desirably, are followed by a booster injection at periods of from 1 to 3 years.

20 The subject matter which applicants regard as their invention is particularly pointed out and distinctly claimed as follows:

25

30

WHAT IS CLAIMED IS:

1. A vesicular, antigenic, immunogenic, non-pyrogenic complex obtained from strains of N. gonorrhoeae characterized by containing protein, carbohydrate, lipids, phosphate and hexosamines, and being characterized on SDS-polyacrylamide gel electrophoresis by sub-unit bands having molecular weights ranging from 150,000 to 15,000.

2. The immunogenic complex of Claim 1 characterized by containing on a dry weight basis about 70-90% protein, about 1.5-5.5 total carbohydrate, about 0.45-0.55% ketodeoxyoctanoate, about 1.1-1.6% RNA, about 0-1.5% DNA, about 0.4-3.5% total lipid, about 0.4-0.65% total phosphate and about 1.0-3.5% hexosamines and being characterized on SDS-polyacrylamide gel electrophoresis by sub-unit bands having molecular weights of about 150,000, 115,000, 90,000, 70,000, 45,000, 39,000-35,000, 32,000-22,000 and 20,000-15,000.

3. A composition comprising an effective amount of the complex of Claim 1 in combination with a physiologically acceptable medium.

4. A composition of Claim 3 wherein the physiologically acceptable medium is saline.

5. A composition of Claim 4 additionally containing alum in an amount sufficient to afford up to 1.25 mg of aluminum by assay per dose.

5 6. A vaccine comprising an effective amount of the complex of Claim 1 in sterile form in combination with a physiologically acceptable medium.

10 7. A vaccine according to Claim 6 wherein the physiologically acceptable medium is saline.

15 8. A vaccine according to Claim 7 additionally containing alum in an amount sufficient to afford up to 1.25 mg of aluminum by assay per dose.

20 9. A method of obtaining the immunogenic complex according to Claim 1 which comprises cultivating N. gonorrhoeae on a suitable nutrient medium, harvesting and centrifuging the cells at 5000xg at 2-4°C; extracting the cell pellet with 5% TRITON X-100 in the presence of tris(hydroxymethyl)-amino ethane and magnesium chloride at alkaline pH; suspending the solids remaining after extraction in aqueous medium and precipitating with cold ethanol; 25 suspending the ethanol precipitate in physiological saline and incubating with DNase and RNase; removing nucleases and degradation products by diafiltration; and purifying by sonication and filtration through a 0.45µm polysulphone filter.

30

10. The process of Claim 9 wherein the ethanol precipitation is carried out at about -20°C .

5 11. The process of Claim 9 wherein sonication is carried out by probe sonication at $0-8^{\circ}\text{C}$.

10

15

20

25

30

110

Date

A1



European Patent
Office

EUROPEAN SEARCH REPORT

0073169

Application number

EP 82 40 1547

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
Y	US-A-4 220 638 (YASHWANT D. KARKHANIS et al.) * Column 1, line 60 - column 2, line 59 *	1-11	A 61 K 39/095
P,Y	US-A-4 288 557 (YASHWANT D. KARKHANIS et al.) * Column 1, line 60 - column 2, line 59 *	1-11	
Y	EP-A-0 002 645 (MERCK & CO.) * Page 1, line 1 - page 3, line 26 *	1-11	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 3)
			A 61 K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 28-02-1984	Examiner REMPP G.L.E.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone. Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

